NCT00652574 2022-10-31
Dasatinib in Resectable Malignant Pleural Mesothelioma
M.D. Anderson Cancer Center
Phase 1 Completed
M.D. Anderson Cancer Center
Mayo Clinic
Alliance for Clinical Trials in Oncology
University of Pittsburgh
M.D. Anderson Cancer Center